Company intelligence / Profile preview

Claris

Jersey City, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Claris Bio is developing a topical ocular biologic (recombinant dHGF) aimed at restoring corneal integrity in diseases such as limbal stem cell deficiency; preclinical and third-party studies have demonstrated biological activity, and the lead program is in late-stage clinical development[1][9].

Therapeutic areas: Ophthalmology
Modalities: BiologicProtein
Industry: Biotech

Partnerships

Massachusetts Eye and Ear Infirmary (IP licensure)Kringle Pharma (drug substance supply agreement)

Beyond the preview

Go deeper on Claris.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Claris.

Explore the full profile